Profile Image

Staff Profile

Edit

Career Summary

Biography

Dr Gough Au is a conjoint Post Doctoral Research Fellow with the University of Newcastle and works for the Australian oncolytic virotherapy company Viralytics Ltd. Dr Au began his career as a NHMRC Industry Research fellow (2007-2011) carrying out research on the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma.

Qualifications

  • PhD, University of Newcastle, 13/09/2005
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle, 14/12/2000
  • Bachelor of Biomedical Sciences, University of Newcastle, 02/12/1999

Research

Research keywords

  • Carcinogenesis
  • Clinical sciences
  • Oncology
  • oncolytic virotherapy
  • virology

Research expertise

Oncolytic virotherapy, Virology & Cancer Biology

Languages

  • English

Fields of Research

CodeDescriptionPercentage
110300Clinical Sciences35
030499Medicinal And Biomolecular Chemistry Not Elsewhere Classified35
111299Oncology And Carcinogenesis Not Elsewhere Classified30

Appointments

Fellowship
National Health & Medical Research Council (Australia)
01/05/2007 - 01/04/2011

Collaboration

Gough's main research interest is in the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma. Other interests include Oncolytic virotherapy, Virology and Cancer Biology.

Administrative

Administrative expertise

Animal Care and Ethics Committee member (2011- to present)

Faculty of Health - Work Health and Safety Group

Teaching

Teaching expertise

PHAR6124 Virology Lectures

HUBS3204 Lab Professional Skills - Commercialisation of Science and Biotechnology Startup Companies

Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Journal article (12 outputs)

YearCitationAltmetricsLink
2014McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, (2014)
2014McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014)
2013Kok CC, Au GG, 'Novel marker for recombination in the 3'-untranslated region of members of the species Human enterovirus A', ARCHIVES OF VIROLOGY, 158 765-773 (2013) [C1]
2011Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
2009Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
2008Howland LJ, Au GG, Barry RD, Shafren DR, 'Potent oncolytic activity of human enteroviruses against human prostate cancer', Prostate, 68 577-587 (2008) [C1]
2007Au GG, Lincz L, Enno A, Shafren DR, 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma', British Journal of Haematology, 137 133-141 (2007) [C1]
2005Au GG, Lindberg AM, Barry RD, Shafren DR, 'Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21', International Journal of Oncology, 26 1471-1476 (2005) [C1]

Co-authors: DARREN SHAFREN

2004Hansbro NG, Johansson ES, Au GG, Lindberg A, Barry RD, Shafren DR, 'Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection', Journal of Virology, 78 1431-1439 (2004) [C1]
2004Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
2003Newcombe NG, Andersson P, Johansson ES, Au GG, Lindberg AM, Barry RD, Shafren DR, 'Cellular receptor interactions of C-cluster human group A coxsackieviruses', JOURNAL OF GENERAL VIROLOGY, 84 3041-3050 (2003)
2000Tooney PA, Au GG, Chahl LA, 'Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex', Neuroscience Letters, 283 185-188 (2000) [C1]

Co-authors: PAUL TOONEY

Show 9 more

Conference (8 outputs)

YearCitationAltmetricsLink
2011Shafren DR, Farrelly M, Croft AJ, Davies B, Stewart J, Ingham R, et al., 'CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]

Co-authors: DARREN SHAFREN

2011Shafren DR, Au GG, Davies B, Chan E, Stewart J, 'Pre-clinical oncolytic activity of coxsackievirus a21 in pancreatic cancer', Annals of Oncology, Barcelona, Spain (2011) [E3]

Co-authors: DARREN SHAFREN

2011Yee YWV, Chan SHE, Shafren DR, Au GG, 'Oncolytic activity of coxsackievirus A21 in human lung cancer: A novel targeted anti-cancer strategy', Journal of Thoracic Oncology, Amsterdam, The Netherlands (2011) [E3]

Co-authors: DARREN SHAFREN

2007Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
2006Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
2005Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
2005Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
2000Tooney PA, Au GG, Chahl LA, 'Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain', Proceedings of the Australian Physiological and Pharmacological Society Symposium Tachykinins: The Challenge Continues, Newcastle, Australia (2000) [E1]

Co-authors: PAUL TOONEY

Show 5 more
Edit

Grants and Funding

Summary

Number of grants9
Total funding$595,774

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2011 (3 grants)

Maitland Cancer Appeal Committee Donation - Lung Cancer Mouse Model$50,000
Funding Body: Maitland Cancer Appeal Committee

Project Team
Professor Phil Hansbro, Professor Paul Foster, Doctor Gough Au
SchemeRole
Research Project Investigator
Total AmountFunding StartFunding Finish
$50,00020112011
GNo:G1100246

SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor Phil Hansbro, Professor Paul Foster, Professor Joerg Mattes, Doctor Simon Keely, Doctor Jay Horvat, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Catherine Ptaschinski, Doctor Kelly Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Laureate Professor John Aitken, Conjoint Professor Keith Jones, Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$45,00020112011
GNo:G1100037

World Cancer Congress 2011, World Expo Center, Dalian, China, 22 - 25 May 2011$1,500
Funding Body: University of Newcastle - Faculty of Health and Medicine

Project Team
Doctor Gough Au
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,50020112011
GNo:G1100576

2010 (1 grants)

Control of malignant glioma by naturally occurring oncolytic enteroviruses.$85,188
Funding Body: Cancer Australia

Project Team
Doctor Gough Au
SchemeRole
Priority-driven Collaborative Cancer Research SchemeChief Investigator
Total AmountFunding StartFunding Finish
$85,18820102010
GNo:G0190325

2009 (2 grants)

The use of Coxsackievirus A21 as a therapy for multiple myeloma and malignant glioma$30,000
Funding Body: Ramaciotti Foundations

Project Team
Doctor Gough Au
SchemeRole
Establishment GrantChief Investigator
Total AmountFunding StartFunding Finish
$30,00020092009
GNo:G0189325

5th International Meeting on Replicating Oncolytic Virus Therapeutics, Banff Canada, 18-21 March 2009$1,700
Funding Body: University of Newcastle - Faculty of Health and Medicine

Project Team
Doctor Gough Au
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,70020092009
GNo:G0189949

2008 (1 grants)

New Staff Grant$5,379
Funding Body: University of Newcastle

Project Team
Doctor Gough Au
SchemeRole
New Staff GrantChief Investigator
Total AmountFunding StartFunding Finish
$5,37920082008
GNo:G0188610

2007 (2 grants)

Coxsackievirus A21 virotherapy of multiple myeloma and malignant glioma$369,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Gough Au
SchemeRole
Industry Research FellowshipsChief Investigator
Total AmountFunding StartFunding Finish
$369,00020072010
GNo:G0186779

The use of Coxsackie B group viruses as potential treatments for human gastric and colorectal cancers$8,007
Funding Body: University of Newcastle

Project Team
Doctor Gough Au
SchemeRole
Early Career Researcher GrantChief Investigator
Total AmountFunding StartFunding Finish
$8,00720072007
GNo:G0188074
Edit

Research Supervision

Number of current supervisions4
Total current UoN PhD EFTSL2.15

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Current Supervision

CommencedProposed
Completion
ProgramSupervisor TypeResearch Title
20142018PhD (Immunology & Microbiol)Principal SupervisorInvestigation of Oncolytic CVA21 as a Potential Treatment for Pancreatic Cancer
20122016PhD (Immunology & Microbiol)Co-SupervisorInvestigating the Mechanisms of Tobacco Cigarette Smoke-Induced Lung Cancer
20112015PhD (Immunology & Microbiol)Principal SupervisorCombination of Oncolytic Coxsackievirus A21 with Conventional Chemotherapy for the Treatment of Melanoma
20112015PhD (Immunology & Microbiol)Principal SupervisorInvestigation of Oncolytic Coxsackievirus A21 as a Potential Treatment for Lung Cancer

Past Supervision

YearProgramSupervisor TypeResearch Title
2014PhD (Immunology & Microbiol)Principal SupervisorLow Pathogenic Human Enteroviruses as Novel Anti-Cancer Agents Against Malignant Glioma
Edit

Dr Gough Au

Work Phone(02) 404 20253
Fax(02) 404 20027
Email
PositionConjoint Fellow
Viralytics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
The University of Newcastle, Australia
Focus AreaImmunology and Microbiology
Office
2420,
HMRI building,
Level 2, HMRI Building East Wing
URL:www.newcastle.edu.au/profile/gough-au
Linkhttp://www.mendeley.com/profiles/gough-au/